当前位置:APASL-en-亚太肝脏研究协会年会 >> 正文
[APASL2013]Responses and Adverse Effects of Triple Therapy with Telaprevir, PegIFN and Ribavirin in Patients with Hepatitis C Virus Infection
—— 作者: 时间:2013-06-07
阅读数:
317
简介:Although triple therapy with telaprevir, PegIFN and ribavirin is associated with adverse events, a higher eradication of HCV can be achieved by carefully monitoring any adverse events and predicting the therapeutic effects based on previous therapy.
请登录后查看详细内容
标签:
摘要赏析
摘要赏析
丙肝
发表评论
全部评论